Benitec BiopharmaBNTC +4.34%34 3-Year ROIIC % is -48,797.96 as of Jun. 2025. GuruFocus rates BNTC with a GF Score™ of 34/100. Among 1,324 Biotechnology companies, Benitec Biopharma ranks worse than 100% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Benitec Biopharma's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was -48,797.96%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Benitec Biopharma's 3-Year ROIIC % or its related term are showing as below:
BNTC's 3-Year ROIIC % is ranked worse than 100% of 1324
companies
in the Biotechnology industry
Industry Median: -4.42
vs BNTC: -48797.96
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Benitec Biopharma 3-Year ROIIC % Related Terms
Benitec Biopharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Benitec Biopharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BNTC vs IPSC, FBRX, AUTL: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Benitec Biopharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Benitec Biopharma 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Benitec Biopharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Benitec Biopharma's 3-Year ROIIC % falls into.
Benitec Biopharma's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -41.765 (Jun. 2025) - -17.854 (Jun. 2022) )
/
( 1.854 (Jun. 2025) - 1.805 (Jun. 2022) )
=
-23.911
/
0.048999999999999
=
-48,797.96%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Benitec Biopharma (BNTC) has a 3-Year ROIIC % of -48,797.96 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Benitec Biopharma and its competitors. According to the industry distribution chart, Benitec Biopharma ranks #1324 out of 1324 companies in the Biotechnology industry.
Is Benitec Biopharma's 3-Year ROIIC % too high?
Benitec Biopharma's current 3-Year ROIIC % is -48,797.96. Based on the distribution chart, Benitec Biopharma ranks #1324 out of 1324 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Benitec Biopharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Benitec Biopharma's 3-Year ROIIC % compare to IPSC and FBRX?
According to the Biotechnology industry distribution chart, Benitec Biopharma ranks #1324 out of 1324 companies for 3-Year ROIIC %. This places Benitec Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Benitec Biopharma and its competitors. Benitec Biopharma's current 3-Year ROIIC % is -48,797.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Benitec Biopharma stock overvalued right now?
Benitec Biopharma (BNTC) has a current 3-Year ROIIC % of -48,797.96. The current 3-Year ROIIC % is -48,797.96. Benitec Biopharma's overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Benitec Biopharma (BNTC), the current 3-Year ROIIC % is -48,797.96 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
34GF Score
Get the complete analysis for BNTC
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNTC has been successfully added to your 
